PharmaShots | Incisive News in 3 Shots

Subscribe Now

Multiple Chronic Inflammatory Diseases

Celltrion Receives EC's Approval for Yuflyma (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

Celltrion Receives EC's Approval for Yuflyma (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

February 16, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us